All HHS Contracts — May 13, 2026

BAVARIAN NORDIC A/S received a $1,264,240,981 HHS contract awarded 2017-08-24, signaling strong positioning in HHS priorities despite limited details on competition or revenue impact.

$163,082,415 obligated (cost-plus-fixed-fee, $62M outlayed) for vaccine manufacturing through 2030-09-30, with options to $240,940,070 via full and open competition.

$147,062,009 obligated (cost-no-fee, $88M outlayed) for vaccine R&D through 2027-09-30, base + options $149,747,956 via full and open competition.

Albert B. Sabin Vaccine Institute, Inc. (nonprofit) holds 20% of period total ($310M across two HHS BARDA contracts), limiting direct equity upside for investors.

BAVARIAN NORDIC A/S $1.26B contract lacks data on pricing risk, competition, or annual revenue est., reducing signal clarity despite high materiality.

Albert B. Sabin Vaccine Institute, Inc. options for $78M additional on $163M Sudan Ebolavirus contract and $2.7M on $147M Marburg/Sudan contract via BARDA/ASPR.

Two $310M contracts to Albert B. Sabin Vaccine Institute, Inc. fund Sudan Ebolavirus and Marburg vaccines (NAICS 541714) through 2030, with $150M outlayed; complements $1.26B BAVARIAN NORDIC A/S award in outbreak R&D.

{"entity"=>"BAVARIAN NORDIC A/S", "reason"=>"$1.26B HHS contract dominates 80% of period obligations but lacks revenue/pricing details.", "trigger"=>"outlay or modification announcements"}

{"entity"=>"Albert B. Sabin Vaccine Institute, Inc.", "reason"=>"$310M combined obligations with $150M outlayed and options to $390M across two BARDA contracts.", "trigger"=>"option exercise toward $240M/$149M ceilings; outlay beyond $62M/$88M"}